PRESS RELEASE published on 08/14/2026 at 10:27, 1 month 28 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Innate Pharma prices €30 million offering of Ordinary Shares at €1.70 per share in Marseille, France. Proceeds will fund clinical development and ADC portfolio advancement Ordinary Shares Clinical Development Offering Innate Pharma ADC Portfolio
BRIEF published on 08/13/2026 at 22:05, 1 month 29 days ago Innate Pharma Launches €22.5 Million Share Offering Euronext Paris Clinical Development Share Offering Innate Pharma Institutional Buyers
PRESS RELEASE published on 08/13/2026 at 22:00, 1 month 29 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Innate Pharma announces proposed offering of ordinary shares worth approximately t €22.5 million, anchored by global coordinator Stifel, for continued clinical development and corporate purposes Ordinary Shares Clinical Development Offering Innate Pharma Stifel
BRIEF published on 08/10/2026 at 08:35, 2 months 1 day ago Innate Pharma Advances Lacutamab into Phase 3 Trial with Sobi Innate Pharma Lacutamab Phase 3 TELLOMAK-3 Markus Jensen Sobi Partnership
BRIEF published on 05/19/2026 at 07:05, 4 months 24 days ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 4 months 24 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
PRESS RELEASE published on 05/19/2026 at 07:00, 4 months 24 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
BRIEF published on 04/17/2026 at 21:05, 5 months 24 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 5 months 24 days ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
PRESS RELEASE published on 04/17/2026 at 21:00, 5 months 24 days ago Inside Information / Other news releases Innate Pharma to present interim results of IPH5201 in MATISSE Phase 2 study at AACR 2026. Study aims to enhance NSCLC treatment with anti-CD39 monoclonal antibody NSCLC Innate Pharma AACR 2026 MATISSE Phase 2 IPH5201
Published on 10/10/2026 at 04:45, 2 days 2 hours ago Immutable Holdings and Jorge Masvidal's Gamebred Fighting Championship (FC) Enter Into Definitive Agreement for Proposed Reverse Takeover Transaction and Listing on the TSXV
Published on 10/10/2026 at 02:03, 2 days 5 hours ago BrandPilot AI Announces Closing of Previously Announced Debt Settlement
Published on 10/10/2026 at 02:00, 2 days 5 hours ago Battery X Metals Reports Estimated Driving Range Increase of Approximately 101 Kilometers Following a Single-Electric-Vehicle Performance Evaluation of Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Technology
Published on 10/09/2026 at 23:00, 2 days 8 hours ago Trans Canada Gold Closes First Tranche of Non-Brokered Private Placement for Gross Proceeds of CDN $2,144,720
Published on 10/09/2026 at 22:15, 2 days 8 hours ago Loop Industries to Host Second Quarter Fiscal 2027 Earnings Conference Call
Published on 10/12/2026 at 07:00, 12 minutes ago EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement
Published on 10/12/2026 at 07:00, 12 minutes ago Nordex Group order intake rises 29.5% to 2.8 GW in the third quarter of 2026
Published on 10/12/2026 at 06:30, 42 minutes ago Centiel obtains UL certification and receives USD 51 million U.S. purchase order; U.S. deliveries expected in 2027 and 2026 guidance revised
Published on 10/12/2026 at 06:05, 1 hour 6 minutes ago SWI Group announces €800 million institutional capital increase at a €6.1 billion final valuation to accelerate the expansion of its transatlantic AI infrastructure and compute platform
Published on 10/12/2026 at 05:00, 2 hours 12 minutes ago ATOMS, Led by Travis Kalanick, Secures $1.7B to Power the Future of Food Delivery with ProKitchens in Europe
Published on 10/09/2026 at 19:27, 2 days 11 hours ago Disclosure of transactions in own shares from October 1 to October 9, 2026
Published on 10/08/2026 at 18:30, 3 days 12 hours ago Cegedim: Release of its 2026 Interim Financial Report
Published on 10/08/2026 at 18:00, 3 days 13 hours ago Launch of LINK, the next generation of THIN: Clinityx’s first European Health Data Warehouse, approved by the French Data Protection Authority for 10 years
Published on 10/08/2026 at 17:45, 3 days 13 hours ago Carrefour announces a real estate sale and leaseback transaction involving 35 stores in France and Spain
